Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Immunogenicity of meningococcus C vaccination in a patient with atypical hemolytic uremic syndrome (aHUS) on eculizumab therapy.

Zlamy M, Hofer J, Elias J, Vogel U, Frosch M, Jungraithmayr T, Zimmerhackl LB, Prelog M.

Pediatr Transplant. 2012 Sep;16(6):E246-50. doi: 10.1111/j.1399-3046.2011.01585.x. Epub 2011 Oct 4.

PMID:
21967634
2.

Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.

Yamamoto T, Watarai Y, Futamura K, Okada M, Tsujita M, Hiramitsu T, Goto N, Narumi S, Takeda A, Kobayashi T.

Transplant Proc. 2017 Jan - Feb;49(1):159-162. doi: 10.1016/j.transproceed.2016.10.013.

PMID:
28104125
3.

Living kidney transplantation in adult patients with atypical haemolytic uraemic syndrome.

Verhave JC, Westra D, van Hamersvelt HW, van Helden M, van de Kar NC, Wetzels JF.

Neth J Med. 2013 Sep;71(7):342-7.

4.

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.

Transplant Proc. 2012 Dec;44(10):3037-40. doi: 10.1016/j.transproceed.2012.07.141.

PMID:
23195022
5.

Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.

Ranch D, Crowther B, Arar M, Assanasen C.

Pediatr Transplant. 2014 Sep;18(6):E185-9. doi: 10.1111/petr.12290. Epub 2014 Jun 14.

PMID:
24931815
6.

Use of eculizumab and plasma exchange in successful combined liver-kidney transplantation in a case of atypical HUS associated with complement factor H mutation.

Tran H, Chaudhuri A, Concepcion W, Grimm PC.

Pediatr Nephrol. 2014 Mar;29(3):477-80. doi: 10.1007/s00467-013-2630-5. Epub 2013 Nov 13.

PMID:
24221349
7.

Liver transplantation for aHUS: still needed in the eculizumab era?

Coppo R, Bonaudo R, Peruzzi RL, Amore A, Brunati A, Romagnoli R, Salizzoni M, Galbusera M, Gotti E, Daina E, Noris M, Remuzzi G.

Pediatr Nephrol. 2016 May;31(5):759-68. doi: 10.1007/s00467-015-3278-0. Epub 2015 Nov 24.

8.

Atypical hemolytic uremic syndrome recurrence after kidney transplantation.

Matar D, Naqvi F, Racusen LC, Carter-Monroe N, Montgomery RA, Alachkar N.

Transplantation. 2014 Dec 15;98(11):1205-12. doi: 10.1097/TP.0000000000000200.

PMID:
24933457
9.

Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome.

Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S.

Pediatr Nephrol. 2011 Aug;26(8):1325-9. doi: 10.1007/s00467-011-1879-9. Epub 2011 May 10.

PMID:
21556717
10.

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.

Schalk G, Kirschfink M, Wehling C, Gastoldi S, Bergmann C, Hoppe B, Weber LT.

Pediatr Nephrol. 2015 Jun;30(6):1039-42. doi: 10.1007/s00467-015-3078-6. Epub 2015 Mar 10.

PMID:
25752761
11.

Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count.

Dorresteijn EM, van de Kar NC, Cransberg K.

Pediatr Nephrol. 2012 Jul;27(7):1193-5. doi: 10.1007/s00467-012-2130-z. Epub 2012 Mar 8.

12.

Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.

Sharma S, Pradhan M, Meyers KE, Le Palma K, Laskin BL.

Clin Nephrol. 2015 Sep;84(3):181-5. doi: 10.5414/CN108532.

13.

Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome.

Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B.

Pediatrics. 2014 Jun;133(6):e1764-8. doi: 10.1542/peds.2013-1594.

14.

Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy.

Hisano M, Ashida A, Nakano E, Suehiro M, Yoshida Y, Matsumoto M, Miyata T, Fujimura Y, Hattori M.

Pediatr Int. 2015 Apr;57(2):313-7. doi: 10.1111/ped.12469.

PMID:
25868950
15.

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.

Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G.

J Thromb Haemost. 2014 Sep;12(9):1440-8. doi: 10.1111/jth.12615. Epub 2014 Jul 16.

16.

Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.

Dedhia P, Govil A, Mogilishetty G, Alloway RR, Woodle ES, Abu Jawdeh BG.

Transplant Proc. 2017 Jan - Feb;49(1):188-192. doi: 10.1016/j.transproceed.2016.11.008.

PMID:
28104134
17.

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W.

N Engl J Med. 2010 May 6;362(18):1746-8. doi: 10.1056/NEJMc1001060. No abstract available.

18.

Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein.

Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P.

Am J Transplant. 2012 Jul;12(7):1938-44. doi: 10.1111/j.1600-6143.2012.04051.x. Epub 2012 Apr 11.

19.

Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?

Saland J.

Pediatr Nephrol. 2014 Mar;29(3):329-32. doi: 10.1007/s00467-013-2722-2. Epub 2013 Dec 22.

PMID:
24362724
20.

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.

Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD.

Pediatr Nephrol. 2011 Nov;26(11):2085-8. doi: 10.1007/s00467-011-1989-4. Epub 2011 Aug 30.

PMID:
21877169

Supplemental Content

Support Center